Assessment of Efficacy, Safety and Dosing of Clevidipine in Pediatric Participants Undergoing Surgery (PIONEER)

Inclusion Criteria: * Less than 18 years of age * Written informed consent obtained before initiation of any study-related procedures * The enrolling physician determines that the participant will likely require a 15% reduction in BP during the perioperative course * Intra-arterial line is available for blood pressure monitoring * Surgical procedure requiring a minimum of 1 hour of anesthesia, in which IV antihypertensive therapy to control BP for at least 30 minutes is anticipated Exclusion Criteria: * Administration of an IV or oral antihypertensive agent within 2 hours prior to study drug administration * Congenital heart disease described as single ventricle * Evidence of liver failure, severe liver disease, pulmonary disease (e.g. uncontrolled asthma), hyperlipidemia, lipoid nephrosis, lipid dysfunction or acute pancreatitis * Allergy to soya bean oil or egg lecithin * Known to be intolerant to calcium channel blockers * Hemophilia or blood coagulation disorders * Any serious medical condition which, in the opinion of the investigator, is likely to interfere with study procedures * Clinically significant abnormal physical findings at the screening evaluation * Any serious surgical or medical condition which, in the opinion of the investigator, is likely to interfere with study procedures or with the pharmacokinetics or pharmacodynamics of the study drug * Participant is terminally ill (death likely to occur within 48 hours) * Use of Methylphenidate, calcium channel bl…